Results 311 to 320 of about 156,767 (359)

Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase

Thrombosis Research, 1987
The activation of a native form of plasminogen (Glu-plg) by tissue plasminogen activator(t-PA) was enhanced when the plasma was clotted by the addition of thrombin or thrombin plus Ca++. Cross-linking of fibrin in the clotted plasma did not inhibit the fibrin-associated enhancement of the activation of plasminogen by t-PA.
Masaru Cho, Kengo Shizume, Akikazu Takada, Yumiko Takada   +3 more
openaire   +3 more sources

Studies on the kinetics of plasminogen activation by tissue plasminogen activator

Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1982
The steady-state rate of plasminogen activation by tissue plasminogen activator has been determined at various plasminogen concentrations. A plasmin substrate method similar to that presented by Christensen and Müllertz (Biochim. Biophys. Acta 480 (1977) 257-281) was used.
openaire   +3 more sources

Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator

Thrombosis Research, 1990
Here experimental evidence is presented demonstrating that Lp(a) inhibits the activation of Pg by the physiologic activator tissue-type plasminogen activator (t-PA) bound to fibrinogen fragments. The competitive inhibition constant, Kie, of the Lp(a) inhibition is 22 nM, or 8.6 mg/dL which corresponds to normal plasma ...
Jay M. Edelberg, Mario Gonzalez-Gronow, Salvatore V. Pizzo   +2 more
openaire   +3 more sources

Claims on tissue plasminogen activator

Nature, 1989
A 'master' patent on a recombinant protein product has twice been overturned in British courts. The consequences may be far-reaching.
openaire   +3 more sources

Kinetic studies of plasminogen activation by epithelial tissue plasminogen activator

Blood Coagulation & Fibrinolysis, 1990
Initial-rate kinetic studies of the activation of plasminogen by epithelial activator were performed in the absence and in the presence of fibrinogen and CNBr-digested fibrinogen, under assay conditions similar to those described by Hoylaerts et al. (J Biol Chem, 257, 2912, 1982).
A Electricwala, R J Ling, Atkinson T
openaire   +3 more sources

Tissue Plasminogen Activator (tPA)

2015
Tissue plasminogen activator (tPA) is used in the setting of acute ischemic stroke. tPA is also utilized for several additional thrombolytic indications, including acute MI, pulmonary embolism, and central venous catheter occlusion.
Juan E. Small, Evan Watkins, Daniel Thomas Ginat   +2 more
openaire   +2 more sources

Efficacy and safety of tissue plasminogen activator

Neurosurgery, 1987
Simple aspiration to remove acute intracerebral hematomas has been thwarted by the solidity of the clot. Urokinase, a first generation fibrinolytic agent, has been used to liquefy such clots with some success. Therefore, tissue plasminogen activator (t-PA), a second generation fibrinolytic drug that may be safer and more effective, was studied to ...
David Bernstein, Sydney S. Schochet, Joyce Herschberger, Howard H. Kaufman, William Koss   +4 more
openaire   +3 more sources

Content of Tissue Activator of Plasminogen in Monkey Tissues

Thrombosis and Haemostasis, 1957
SummaryThe content of the tissue activator of plasminogen in various organs from monkey is generally lower than in the corresponding human organs and approaches the concentration in the organs of other animals.
H. R Roberts, Tage Astrup
openaire   +3 more sources

Activation of Val442-plasminogen (mini-plasminogen) by urokinase, streptokinase and tissue plasminogen activator

Thrombosis Research, 1988
Glu-plasminogen (Glu-plg), Lys-plg and Val442-plg (mini-plg) were activated by urokinase (UK), streptokinase (SK) or tissue plasminogen activator (t-PA). Their activation rates were kinetically analyzed. UK activated Lys-plg with smaller Km and nearly identical Vmax as Glu-plg.
Yoshiaki Sugawara, Akikazu Takada, Yumiko Takada   +2 more
openaire   +2 more sources

Tissue Plasminogen Activator and the Corneal Endothelium

American Journal of Ophthalmology, 1989
• There is a potential risk of bacterial or fungal contamination of the initial preparation, which could then result in contamination of each of the individual doses. It is essential, therefore, that the tissue plasminogen activator be reconstituted under strict aseptic conditions in a sterile hood.
Mark L. McDermott, Henry F. Edelhauser, Steven B. Koenig, Robert A. Hyndiuk   +3 more
openaire   +3 more sources